Navigation Links
Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
Date:10/14/2008

Drug User Fee Act (PDUFA) goal date will be 16 January 2009. Arpida submitted a Marketing Authorisation Application for intravenous iclaprim with EMEA in July 2008. EMEA notified that it had accepted the MAA for review in August 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In May 2008, Arpida announced the enrolment of the first patients in a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Results of "first-in-man" studies with AR-709 were published in March 2007.

An additional antibacterial compound, AR-2474, has demonstrated in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assu
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
2. Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
3. Arpida Provides Further Comments on the Pivotal Phase III Trials
4. Arpida Invited to Present Data on Iclaprim at Scientific Conference
5. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
6. Facet Solutions Announces Completion of 6 Month Follow-Up in US Pilot Study
7. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
8. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
9. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
10. In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices
11. Burcon announces GRAS status for Puratein(R) & Supertein(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  In recognition of Rare Disease Day and ... bleeding disorders community, CSL Behring announced today ... of protein therapies to the World Federation of Hemophilia ... has worked to improve the lives of people with ... the WFH,s Global Alliance for Progress (GAP) Program aimed ...
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, ... company focused on delivering breakthrough 3D bioprinting technology, ... and Chief Executive Officer, will present live at ... invite you to join us for this Company ... updates on our commercial launch of the exVive3D ...
(Date:2/27/2015)...  Bionik Laboratories Corp. (OTC:DWTPD), a Delaware ... acquired Bionik Laboratories, Inc., a Toronto ... qualified accredited investors of units consisting of its common ... $6.2 million. Shares of the Company,s common stock will ... the symbol "DWTPD" until FINRA,s approval of the ticker ...
Breaking Medicine Technology:CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3
... Patient enrollment begins for trial of airway bypass ... April 1, 2008 Researchers at,Suburban Lung Associates ... of the EASE (Exhale Airway Stents for Emphysema) ... emphysema. The trial,focuses on airway bypass, a minimally ...
... Across a ... Spectrum of Patients, ... MitraClip(R) device may successfully reduce mitral regurgitation (MR),in patients suffering ... data from the ongoing Endovascular Valve,Edge-to-Edge REpair STudy (EVEREST) presented ...
Cached Medicine Technology:Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital 2Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital 3Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital 4MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients 2MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients 3MitraClip Device Preliminary Data Suggests Improved Heart Function and Relief from Heart Failure Symptoms in Functional Mitral Regurgitation Patients 4
(Date:2/28/2015)... IL (PRWEB) February 28, 2015 With ... Chunk Fitness has added an additional exercise to their ... the oblique exercise is most commonly known as, is ... , “Rope Pulls” are executed in a relatively safe ... fitness and strength levels. The full description of “Rope ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently announced ... They stated that in many cases, missing an important time ... Many a time, delays in making an injury claim can ... As a result, experts at Jiwa Law Corporation suggest that ... injury lawyer in order to know more about their rights. ...
(Date:2/28/2015)... February 28, 2015 Pioneer Millworks reclaimed ... Japan Architecture & Construction Materials Show, an annual, premier ... than 1,000 suppliers and top manufacturers of the latest ... wood products sourced and manufactured by Pioneer Millworks ... popularity in Japan at restaurants, hotels, retailers, and corporate ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at Back2Basics Outdoor ... student obtaining her Masters degree in social work at ... psychoeducation on substance use for teens at the local ... her studies. , “Even though these students are young, ... the high school and junior high school level,” said ...
(Date:2/28/2015)... California (PRWEB) February 28, 2015 Developers of ... release of a new overlay plugin for Final Cut Pro ... Studios. , “FCPX Overlay Chromatic gives users total control over ... Christina Austin, CEO of Pixel Film Studios. “FCPX Overlay Chromatic ... an easy to use interface.” , FCPX Overlay Chromatic Grunge ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2
... Quarter Driven by Improved Margins and Higher Sales of ... Pharmaceutical Companies, Inc. (NYSE: PRX ) today ... 2009. Par reported total revenues of $204.0 million and ... share, which included a change in estimate relating to ...
... President Obama,s advice to exercise prudence, but not to ... According to Global Distribution System and Online Travel ... and leisure travel continues, despite a decline to Mexico ... very few cancellations outside of Mexico. Many are ...
... 6 AMN Healthcare Services, Inc. (NYSE: AHS ), ... presentation on Tuesday, May 12, 2009 at 2:40 p.m. Eastern Time ... Conference taking place at the Palace Hotel in New York City, ... at the Robert W. Baird 2009 Growth Stock Conference taking place ...
... Dr. Jan Linhart and wife Ellen honored for generous contribution to ... ... May 6, 2009 -- Dr. Jan Linhart, D.D.S. and his wife, ... Linhart Continuing Dental Education Program at Dr. Linhart’s alma mater. In ...
... the New York tri-state premier monthly magazine for ... will honor its 40 Under Forty achievement award ... annual awards dinner, will be hosted by Shon ... D. Pinkett, Ph.d., co-founder, chairman and CEO of ...
... Calif., May 5 In a year of ... largest union and professional association of registered nurses, ... Committee have endorsed the direction of the organization ... and other incumbent members of the CNA/NNOC Board ...
Cached Medicine News:Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 2Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 3Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 4Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 5Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 6Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 7Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 8Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 9Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 10Health News:Par Pharmaceutical Reports Adjusted EPS of $0.49 for First Quarter 2009 11Health News:AMN Healthcare Services to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference and at the Robert W. Baird 2009 Growth Stock Conference 2Health News:Manhattan Dentist Inducted Into The Sir Harold Acton Society 2Health News:The Network Journal Announces its 2009 List of "40 Under Forty" Dynamic Achievers 2Health News:The Network Journal Announces its 2009 List of "40 Under Forty" Dynamic Achievers 3Health News:The Network Journal Announces its 2009 List of "40 Under Forty" Dynamic Achievers 4Health News:The Network Journal Announces its 2009 List of "40 Under Forty" Dynamic Achievers 5Health News:CNA/NNOC Re-Elects Council of Presidents 2
Biosite continues its tradition of leadership and innovation with the development of the Triage TOX Drug Screen. This breakthrough technology sets new standards for clear, convenient and controlled,...
... Advanced Model 3900 Multi-Sample Osmometer is ... processing moderate to high volumes of ... of freezing-point technology for an accurate ... high, continuous throughput, the Advanced Instruments ...
... Micro-Osmometer is an automated, single-sample osmometer, designed ... 3320 is ideally suited for clinical and ... Model 3320 employs the industry preferred freezing-point ... robust and dependable throughout fifty years of ...
... The Advanced® 2020 Multi-Sample Osmometer ... clinical, industrial, and research settings. These ... industry-preferred freezing-point method, which determines total ... offers on-board data management, automated sample ...
Medicine Products: